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Abstract Recessive congenital methaemoglobinaemia
(RCM) due to NADH-cytochrome b5 reductase (cytb5r)
deﬁciency is a very rare disorder. We report on two
unrelated patients (4 and 2.5 years old) with RCM type
2. Developmental delay was obvious at the age of 4
months. On follow-up, both children showed severe
tetraspastic cerebral palsy, profound cognitive impair-
ment, strabismus, impressive secondary microcephaly
and failure to thrive. One novel mutation in the DI-
A1gene was identiﬁed. Prenatal diagnosis was success-
fully done in both families by mutation analysis in
chorionic villi or measurement of cytb5r in fetal amni-
otic cells. Conclusion: Due to the severity of this disease
and its 25% recurrence risk, prenatal diagnosis should
be made available to all aﬀected families.
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Introduction
In the blood of healthy individuals, less than 1% of
haemoglobin is present in the oxidised form called
methaemoglobin. The major pathway for the reduction
of methaemoglobin to functional haemoglobin in hu-
man erythrocytes involves a NADH-dependent meth-
aemoglobin reductase system. In addition to NADH,
this system requires the presence of cytochrome b5
reductase (cytb5r, also named diaphorase) and cyto-
chrome b5. Recessive congenital methaemoglobinaemia
(RCM) (MIM 250800) is a very rare disorder caused by
deﬁciency of cytb5r. Two forms of this enzyme are
known, a membrane-bound form mainly found in
microsomes and the endoplasmic reticulum of all tissues
investigated [2,17], and a soluble form present in
erythrocytes. These two forms are generated from the
same gene by a combination of transcriptional and
translational mechanisms [3, 10,12]. The enzyme deﬁ-
ciency is usually restricted to the red cell soluble cytb5r
(RCM type 1), whereas in 10%–15% of cases the en-
zyme defect is generalised to all tissues, involving both
soluble and microsomal forms of the enzyme (RCM type
2). Patients with RCM type 1 have cyanosis but hardly
any systemic symptoms when the methaemoglobin level
is less than 25%. In RCM type 2, cyanosis is associated
with severe progressive neurological disability.
RCM type 1 and type 2 are caused by a defect in a
single gene ( DIA1), which has nine exons and eight
introns, and is located on chromosome 22 (locus DIA1;
q13.31-qter) [4]. Recent literature focuses on genetic
aspects and mutation analysis; here we emphasise the
severe neurological outcome of RCM type 2, which is
usually only vaguely described as ‘‘mental retardation’’
or ‘‘neurological impairment’’.
Case reports
Case 1
The patient, a girl, was born at term as the ﬁrst child of healthy
consanguineous Pakistani parents (multiple relationship). Her
weight (3820 g), length (53 cm) and head circumference (32.5 cm)
were within the normal percentile values. Cyanosis was noted
within hours after birth. Methaemoglobin concentration was
increased to 17% of total haemoglobin and fell to 6% after i.v.
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administration of methylene blue (1 mg/kg). Apart from the cya-
nosis, there were no other apparent problems, and RCM type 1 was
suspected.
At the age of 4 months, when developmental delay was already
obvious, the baby was referred to our hospital for further evalua-
tion. Her head circumference was borderline microcephalic
(37.7 cm) and her muscle tone was increased. MRI of the brain
showed enlarged CSF spaces and delayed myelination. Treatment
with ascorbic acid (500 mg daily) and riboﬂavin (40 mg daily) re-
sulted in improvement of methaemoglobinaemia (8%–12%). In the
following months, the parents reported frequent vomiting and
crying, and hardly any progress in psychomotor development was
observed. When last seen at the age of 4 years, the girl showed
marked secondary microcephaly with a head circumference of
43.4 cm (-5.2 SD) (Fig. 1), failure to thrive, short stature, strabis-
mus and profound cognitive impairment. She had no command of
expressive language and was not able to obey simple orders. She
had severe tetraspastic cerebral palsy and was unable to sit, crawl
or grasp objects. Eating was diﬃcult because of poor coordination
of chewing and swallowing. The parents have so far declined the
proposed gastrostomy.
Case 2
The girl was born at term as the ﬁrst child of healthy consan-
guineous Turkish parents (second cousins). Her weight (2750 g),
length (49 cm) and head circumference (33.5 cm) were within the
normal percentile values. Cyanosis developed within hours after
birth. Developmental delay was noted at 4 months. Despite the
persisting cyanosis and extensive investigations, the diagnosis of
RCM was not considered. At the age of 16 months, the child was
referred to our hospital for diagnostic work-up of severe develop-
mental delay.
Methaemoglobin concentration was increased to 35%; ther-
apy with ascorbic acid (1000 mg daily) and riboﬂavin (40 mg
daily) was started and the cyanosis improved markedly. Brain
MRI at the age of 5 months and 16 months showed enlarged
CSF spaces, delayed myelination and a thin corpus callosum.
The parents reported excessive crying and frequent vomiting
resulting in failure to thrive and growth retardation. When last
seen at age of 2.5 years she had severe tetraspastic cerebral palsy
and was unable to sit, crawl, grasp objects or talk. There
was profound cognitive impairment and strabismus. Her head
circumference was 41 cm (-6.5 SD).
There was no evidence for the presence of any abnormal hae-
moglobin as judged by electrophoresis, nor of glucose-6-phosphate
dehydrogenase deﬁciency. Cytb5r was not measurable in the ery-
throcytes of either patient. Semiquantitative tests gave no indica-
tion of reduced activity in the parents. However, a heterozygous
state of 50% reduction would probably not have been detected in
our assay.
Molecular analysis in case 1 has so far failed to identify the
precise mutation, but absence of ampliﬁcation by means of PCR of
exon 2 in the patient (but not in the parents) suggested either a
deletion or large insertion in this exon. Case 2 was shown to be
homozygous for a hitherto unreported missense mutation in exon 8
(Arg 240 Gly). Both parents were heterozygous for this mutation.
In addition, exon 9 could not be ampliﬁed in the patient (but
normally in both parents).
Prenatal diagnosis was successfully done in the mother of case 1
by measurement of cytb5r in fetal amniotic cells. She gave birth to a
healthy child and is currently pregnant again. The mother of case 2
had mutation analysis in chorionic villi and gave birth to a healthy
girl.
Discussion
In a newborn or infant with persisting cyanosis in the
absence of cardiac or pulmonary disease, the diagnosis
of methaemoglobinaemia should be considered. It is
important to rule out acquired forms of methaemo-
globinaemia which are more common than congenital
forms, glucose-6-phosphate dehydrogenase deﬁciency
and haemoglobinopathies. Diminished methaemoglo-
bin reduction rates and methaemoglobinaemia have
been observed with haemoglobins NBaltimore, IToulouse
and MMilwaukee. These mutant haemoglobins presum-
ably fail to interact eﬃciently with cytb5r [5]. The
diagnosis of RCM is established by the measurement
of markedly reduced cytb5r activity in the patients’
erythrocytes.
As patients with RCM type 1 have only mild
symptoms and a normal life expectancy, therapy is
mainly ‘‘cosmetic’’. Oral ascorbic acid (500–1000 mg
daily) and riboﬂavin (20–50 mg daily) can maintain
the methaemoglobin concentration at acceptable levels.
Unfortunately, it has no demonstrable eﬀect on the
progressive neurological dysfunction in patients with
RCM type 2.
RCM type 1 and type 2 are single gene defects.
Mutations that reduce stability and leave catalytic
Fig. 1 Head circumference chart of case 1 illustrating early and
marked secondary microcephaly
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function intact mainly cause problems in the erythro-
cyte, which is dependent on enzymes synthesised in the
reticulocyte persisting for the 120-day life span of the
enucleate red cell [14]. Conversely, mutations that
markedly reduce catalytic function cause problems in all
cells expressing cytb5r and result in the type 2 phenotype
[5].
The microsomal enzyme participates in the desatu-
ration and elongation of fatty acids [7,16] as well as in
cholesterol biosynthesis [13]. It has been suggested that
impairment of fatty acid desaturation, especially in the
central nervous system, may account for the generalised
systemic manifestations [9].
Both our patients presented with cyanosis within
hours after birth. From the clinical viewpoint, the
distinction between RCM types 1 and 2 is impossible
in the newborn. The chemical results (cytb5r, met-
haemoglobinaemia) do not diﬀer either. Mutation
analysis is not a routine procedure and results are not
available within weeks, especially in a ﬁrst aﬀected
child of a family. Therefore prognosis remained open
for the ﬁrst weeks. Lack of normal increase in head
circumference was one of the earliest signs for the
distinction between RCM types 1 and 2. Develop-
mental delay became obvious at the early age of 3–4
months. The symptoms, severe tetraspastic (dystonic)
cerebral palsy, profound cognitive impairment with no
command of expressive language, strabismus, failure
to thrive and growth retardation, are all nonspeciﬁc.
Whether the failure to thrive is the consequence of
cerebral palsy or directly linked to RCM type 2 re-
mains open. The early and impressive secondary
microcephaly is due to the reduced amount of white
matter. The clinical history and the symptoms are
comparable to the case reports in literature, where in
addition, epilepsy and a reduced life expectancy have
been reported [1,15].
The identiﬁcation of diﬀerent mutations at diﬀerent
positions in the DIA1gene should provide insight into
the clinical and biochemical diﬀerences between RCM
types 1 and 2. More than 30 diﬀerent mutations have
been associated with RCM types 1 and 2 [11]. RCM type
2 seems to be more often associated with nonsense
mutations or deletions whereas RCM type 1 seems only
to be associated with amino acid substitutions. These
molecular diﬀerences might lead to variations in stability
or structure of the protein or other enzymatic charac-
teristics, resulting in the clinical diﬀerences between
RCM types 1 and 2 [1,8].
With a recurrence risk of 25%, prenatal diagnosis
in RCM type 2 should be oﬀered to parents with an
aﬀected child. Reliable prenatal diagnosis can be made
at an early stage in chorionic villi if a disease-associated
mutation in the aﬀected child is found. Alternatively,
analysis of cytb5r activity in fetal amniotic cells is
possible because of the generalised defect [6].
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